TRAI issues amended 'Rating Manual 2026' for assessment of Digital Connectivity (See 'Corp Brief') Zojila Tunnel to establish All-Weather Connectivity Between J&K and Ladakh (See 'Corp Brief') Ministry of MSME Promoting Inclusive Entrepreneurship through National SC-ST Hub Scheme (See 'Corp Brief') GeM Boosts MSE Inclusion: Registered Units Rise to 11.9 Lakh (See 'Corp Brief') Strong, transparent and modern cooperative institutions will energise rural economy: Bhutani (See 'Corp Brief') IPR - Foreign FRAND rate-setting action filed by implementer may be treated as relevant material at pro tem stage in assessing prima facie essentiality / need for licensing: HC (See 'Legal Desk') Trade Marks - CALPOL & CALPOL FAST medicines granted status of well-known trademark as material demonstrates strong consumer association of mark with Plaintiff & its distinctiveness in pharma sector: HC (See 'Legal Desk') SAIL sharpens strategic priorities for FY27, reinforces market position (See 'Corp Brief') Railways sanctions upgradation of Electric Traction System on Bengaluru-Tumkur Section (See 'Corp Brief') IBC - Once resolution plan was approved by CoC, successful resolution applicant is bound by it and cannot seek to evade implementation by raising objections to LoI stipulations that are inherent in process: SC (See 'Legal Desk') Railways sanctions upgradation of Electric Traction System on Mahbubnagar-Secunderabad Section (See 'Corp Brief') Capital Market - Finding of 'fraud' under SEBI PFUTP Regulations, 2003, cannot be sustained, if Securities Appellate Tribunal had committed 'egregious error' in affirming SEBI's conclusions on manipulation & fraudulent intent: SC (See 'Legal Desk') MoS inaugurates Self-ticketing Kiosks at National Zoological Park (See 'Corp Brief') Ministry of Panchayati Raj to organise outreach workshop on Atmanirbhar Panchayat Program (See 'Corp Brief') Mandaviya leads nationwide World Bicycle Day celebrations with actor Vikrant Massey (See 'Corp Brief') IPR - Nature of enquiry u/s 57, being one for cancellation or rectification of register, is founded upon appreciation of statutory parameters such as distinctiveness, prior use and likelihood of confusion: HC (See 'Legal Desk') MoS inaugurates Daycare Facility for Children of MSDE Employees at Kaushal Bhawan (See 'Corp Brief') National Biodiversity Authority Celebrates World Environment Day 2026 (See 'Corp Brief') AI-enabled Sayuj App & Open Challenge Program 1.0 launched to strengthen Startup Ecosystem: MoS (See 'Corp Brief') Over 6,000 youth from across country to celebrate innovation & leadership (See 'Corp Brief') IBC - Land leased by statutory authority cannot be excluded from Corporate Debtor's assets on ground that development rights were transferred without consent: NCLT (See 'Legal Desk') IBC's Primacy Over the Electricity Act and the Extinguishment of Pre-CIRP Claims (See CORP EINSICHT)

Print

NPPA monitors prices of scheduled & non-scheduled medicines

Published: Jul 30, 2024

By TIOLCorplaws News Service

NEW DELHI, JULY 30, 2024: AS per the provisions of Drugs (Prices Control) Order, 2013 (DPCO, 2013), formulations listed in Schedule-I of the DPCO are defined as scheduled formulation under section 2(1)(zb) of DPCO, 2013. Formulations not included in Schedule-I are defined under Para 2(1)(v) of DPCO, 2013 as non-scheduled formulation. Thus, both schedule and non-schedule drugs are covered under DPCO, 2013. 

As per the extant provisions of DPCO, 2013, the ceiling prices of scheduled medicines are revised annually on the basis of Wholesale Price Index (WPI) (all commodities) for preceding calendar year by National Pharmaceutical Pricing Authority (NPPA), on or before 1st April of every year and is notified by the Government on the 1st day of April every year. The details of price fixed by NPPA are available at NPPA's website i.e. nppaindia.nic.in.  In case of non-scheduled formulation (branded or generic), as per para 20 of DPCO, 2013, no manufacturers can increase Maximum Retail Price (MRP) by more than 10% of MRP during preceding 12 months.  The maximum permissible increase in prices, as per the provisions of DPCO, 2013 for scheduled and non-scheduled drugs may or may not be availed by their respective manufacturers based on commercial considerations and market dynamics.

Under the Drugs and Cosmetics Act, 1945 and Rules thereunder, manufacturers of drugs are required to comply with conditions of manufacturing licence and the requirements of Good Manufacturing Practices (GMP).  As per the Drugs Rules, 1945, the manufacturing, testing, labeling, packaging, storage and distribution are required to be carried out in compliance with the conditions of license including the Good manufacturing practices (GMP) prescribed under the Schedule M of the Drugs Rules, 1945. In case of violation, the Licensing Authority is empowered to take action as per the said Act and Rules.

NPPA monitors the prices of scheduled as well as non-scheduled medicines under DPCO, 2013.  Action is taken against companies, found selling formulations at prices higher than the permissible price, and the overcharged amount is recovered from the company as per the relevant provisions of the DPCO, 2013. During the financial year 2023-24, Rs. 72.73 crore was recovered from the defaulting companies.

This information was given by the Union Minister of State for Chemicals and Fertilizers Anupriya Patel in Rajya Sabha in reply to a question today.

TIOL CORP SEARCH

TIOL GROUP WEBSITES

taxindiaonline
taxindiainternational
tioltube
TKF
TIOLawards
A TIOL Website. Copyright © 2025 TIOLcorplaws.com All rights reserved.